Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer

Gut

Volumn 57, Issue 10, 2008, Pages 1413-1419

  Zlobec, I ^a   Terracciano, L ^a   Tornillo, L ^a   Gunthert U ^a   Vuong, T ^b   Jass, J R ^c,d   Lugli, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c ST MARK S HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN STERILE 20 LIKE KINASE 1; MISMATCH REPAIR PROTEIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR INFILTRATING LYMPHOCYTE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN A;

ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE MARKER; DISTANT METASTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD44; CHRONIC DISEASE; COLORECTAL NEOPLASMS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 52649176459     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.141192     Document Type: Article

References (36)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5.
3. American Joint Committee on Cancer. AJCC cancer staging manual. 6th edn. New York: Springer, 2002.
4. Benson 3rd AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19.
5. Compton CC. Prognostic factors in cancer. 3rd edn. New York: John Wiley, 2006.
6. Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437-59.
7. Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63:539-43.
8. Nakamura T, Mitomi H, Kikuchi S, et al. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology 2005;52:1432-5.
9. Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127:385-94.
10. Ueno K, Miyazono N, Inoue H, et al. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000;88:1574-81.
11. Zlobec I, Lugli A, Baker K, et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol 2007;212:260-8.
12. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005;23:3526-35.
13. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
14. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
15. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901.
16. Zlobec I, Terracciano L, Jass JR, et al. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 2007,451:763-9.
17. Zlobec I, Steele R, Terracciano L, et al. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007,60:112-6.
18. Zlobec I, Vuong T, Hayashi S, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 2007;96:793-800.
19. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003;2:962-72.
20. Zlobec I, Steele R, Michel RP, et al. Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol 2006;19:1236-42.
21. Kirkegaard T, Edwards J, Tovey S, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006;48:787-94.
22. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care 2004,8:508-12.
23. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:1785-96.
24. Okuno K. Surgical treatment for digestive cancer. Current issues - colon cancer. Dig Surg. 2007;24:108-14.
25. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002;277:4589-92.
26. Goueffic Y, Guilluy C, Guerin P, et al. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res 2006;72:339-48.
27. Abetamann V, Kern HF, Elsasser HP. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res 1996;2:1607-18.
28. Li H, Guo L, Li JW, Liu N, et al.. Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol 2000;17:927-32.
29. Rein DT, Roehrig K, Schondorf T, et al. Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis. J Cancer Res Clin Oncol 2003;129:161- 4.
30. Teder P, Bergh J, Heldin P. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines. Cancer Res 1995;55:3908-14.
31. Yamada Y, Itano N, Narimatsu H, et al. Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction. Jpn J Cancer Pes 1999;90:987-92.
32. Hamilton SR, Fard SF, Paiwand FF, et al. The hyaluronan receptors CD44 and Rhamm (CD168I form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007;282:16667- 80.
33. Lugli A, Zlobec I, Gunthert U, et al. Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Mod Pathol 2006;19:1302-9.
34. Zlobec I, Baker K, Terracciano L, et al. RHAMM, p21 combined phenotype identified microsatellite instability-high colorectal cancer with a highly adverse prognosis. Clin Cancer Res 2008;14:3798-806.
35. Jass JR. Re: Ward et al. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 2006;208:590-1.
36. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007;133:48-56.